Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075355

« Back to Dashboard
NDA 075355 describes LABETALOL HYDROCHLORIDE, which is a drug marketed by Eurohlth Intl Sarl, Par Form, Sandoz, Nostrum Labs Inc, Apothecon, Akorn Inc, Watson Labs, Sagent Strides, Hospira, Claris, Ivax Sub Teva Pharms, Teva, and Gland Pharma Ltd, and is included in seventeen NDAs. It is available from twenty-nine suppliers. Additional details are available on the LABETALOL HYDROCHLORIDE profile page.

The generic ingredient in LABETALOL HYDROCHLORIDE is labetalol hydrochloride. There are twelve drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.

Summary for NDA: 075355

labetalol hydrochloride
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength5MG/ML
Approval Date:Nov 29, 1999TE:RLD:No

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?